August 19, 2024 ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
May 1, 2024 ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
